We found no evidence to support short-term or prolonged feeding with a hydrolysed formula compared with exclusive breast feeding for prevention of allergic disease .
Very low- quality evidence indicates that short-term use of an EHF compared with a CMF may prevent infant CMA .
Further trials are recommended before implementation of this practice .We found no evidence to support prolonged feeding with a hydrolysed formula compared with a CMF for prevention of allergic disease in infants unable to be exclusively breast fed
BACKGROUND Infant formulas containing hydrolysed proteins have been widely advocated for preventing allergic disease in infants , in place of st and ard cow 's milk formula ( CMF ) .
However , it is unclear whether the clinical trial evidence supports this .
OBJECTIVES To compare effects on allergic disease when infants are fed a hydrolysed formula versus CMF or human breast milk .
If hydrolysed formulas are effective , to determine what type of hydrolysed formula is most effective , including extensively or partially hydrolysed formula ( EHF/PHF ) .
To determine whether infants at low or high risk of allergic disease , and whether infants receiving early short-term ( first few days after birth ) or prolonged formula feeding benefit from hydrolysed formulas .
Effect of cow's milk exposure and maternal type 1 diabetes on cellular and humoral immunization to dietary insulin in infants at genetic risk for type 1 diabetes. Finnish Trial to Reduce IDDM in the Genetically at Risk Study Group.
Type 1 diabetes is considered to be a T-cell-mediated autoimmune disease in which insulin-producing beta-cells are destroyed . Immunity to insulin has been suggested to be one of the primary autoimmune mechanisms leading to islet cell destruction . We have previously shown that the first immunization to insulin occurs by exposure to bovine insulin ( BI ) in cow 's milk ( CM ) formula . In this study , we analyzed the development of insulin-specific T-cell responses by proliferation test , emergence of insulin-binding antibodies by enzyme immunoassay , and insulin autoantibodies by radioimmunoassay in relation to CM exposure and family history of type 1 diabetes in infants with a first-degree relative with type 1 diabetes and increased genetic risk for the disease . The infants were r and omized to receive either an adapted CM-based formula or a hydrolyzed casein (HC)-based formula  after breast-feeding for the first 6 - 8 months of life . At the age of 3 months , both cellular and humoral responses to BI were higher in infants exposed to CM formula than in infants fully breast-fed ( P = 0.015 and P = 0.007 ) . IgG antibodies to BI were higher in infants who received CM formula than in infants who received HC formula at 3 months of age ( P = 0.01 ) , but no difference in T-cell responses was seen between the groups . T-cell responses to BI at 9 months of age ( P = 0.05 ) and to human insulin at 12 ( P = 0.014 ) and 24 months of age ( P = 0.009 ) as well as IgG antibodies to BI at 24 months of age ( P = 0.05 ) were lower in children with a diabetic mother than in children with a diabetic father or a sibling , suggesting possible tolerization to insulin by maternal insulin therapy . The priming of insulin-specific humoral and T-cell immunity occurs in early infancy by dietary insulin , and this phenomenon is influenced by maternal type 1 diabetes
We found no evidence to support short-term or prolonged feeding with a hydrolysed formula compared with exclusive breast feeding for prevention of allergic disease .
Very low- quality evidence indicates that short-term use of an EHF compared with a CMF may prevent infant CMA .
Further trials are recommended before implementation of this practice .We found no evidence to support prolonged feeding with a hydrolysed formula compared with a CMF for prevention of allergic disease in infants unable to be exclusively breast fed
BACKGROUND Infant formulas containing hydrolysed proteins have been widely advocated for preventing allergic disease in infants , in place of st and ard cow 's milk formula ( CMF ) .
However , it is unclear whether the clinical trial evidence supports this .
OBJECTIVES To compare effects on allergic disease when infants are fed a hydrolysed formula versus CMF or human breast milk .
If hydrolysed formulas are effective , to determine what type of hydrolysed formula is most effective , including extensively or partially hydrolysed formula ( EHF/PHF ) .
To determine whether infants at low or high risk of allergic disease , and whether infants receiving early short-term ( first few days after birth ) or prolonged formula feeding benefit from hydrolysed formulas .